# Carvedilol in HF With Preserved EF

> **NCT05553314** · PHASE4 · UNKNOWN · sponsor: **Seoul National University Bundang Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Heart Failure With Preserved Ejection Fraction
- Beta Blocker
- Myocardial Strain

## Interventions

- **DRUG:** Carvedilol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05553314
- **Lead sponsor:** Seoul National University Bundang Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-17
- **Primary completion:** 2024-08-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-11-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05553314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05553314, "Carvedilol in HF With Preserved EF". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05553314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*